SVB Wealth’s AbCellera Biologics ABCL Stock Holding History

SVB Wealth’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-20,557	Closed	-$208K	–	1007
2022 Q4	$208K	Hold	20,557	–	–	﹤0.01%	898
2022 Q3	$203K	Buy	+20,557	New	+$226K	﹤0.01%	847

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SVB Wealth's ABCL Position: Q1 2023 in Review

SVB Wealth sold out of AbCellera Biologics (ABCL) in Q1 2023, closing a stake of 20,557 shares — an estimated $208K sold.

SVB Wealth first reported a position in ABCL in Q3 2022 and held it in 2 quarters. The position peaked at $208K in Q4 2022. 183 funds tracked by Wall St. Rank hold ABCL as of Q1 2023.

SVB Wealth reported no remaining AbCellera Biologics position as of Q1 2023 after selling out during the quarter.
SVB Wealth sold 20,557 AbCellera Biologics shares in Q1 2023, an estimated $208K.
SVB Wealth first reported a position in AbCellera Biologics in Q3 2022 and held it in 2 quarters.
SVB Wealth's AbCellera Biologics position peaked at $208K in Q4 2022.
183 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2023.

Based on SVB Wealth's 13F filing for Q1 2023, filed 12 May 2023.